Nxera Pharma Co., Ltd. announced on September 3, 2026, that it will receive an $8.6 million milestone payment from Centessa Pharmaceuticals Limited, a wholly-owned subsidiary of Eli Lilly and Company, according to the sources. The payment is triggered by the achievement of a late-stage development milestone within Centessa’s selective orexin receptor 2 (OX2R) agonist portfolio, a pipeline focused on treatments for sleep-wake regulation and related neurological conditions. According to RTTNews, the financial reward will be booked as revenue in the third quarter of fiscal year 2026.
Acquisition Background and Orexin Pipeline Progress
Eli Lilly and Company completed its acquisition of Centessa earlier in 2026, securing full ownership of the targeted OX2R agonist pipeline. According to financial filings, the $8.6 million distribution flows directly from an existing research collaboration agreement between Nxera and Centessa.
Nxera Pharma retains structural rights to secure additional development and commercialization milestones alongside future royalties tied to the progression of these clinical programs. Christopher Cargill, President and Chief Executive Officer of Nxera Pharma, stated in a corporate release that the company is very pleased to see progress in the clinic and more broadly across the OX2R agonist pipeline, describing the portfolio as a development path with significant potential to address major unmet needs across a broad range of disorders.
Corporate Footprint and Platform Technology
Nxera Pharma operates internationally with corporate locations in Tokyo and Osaka, Japan; London and Cambridge, United Kingdom; Basel, Switzerland; and Seoul, South Korea. The company trades on the Tokyo Stock Exchange under the ticker symbol 4565. According to historical market data cited by RTTNews, Nxera shares traded between JPY 723 and JPY 1,247 over the preceding 52-week window, closing a recent trading session at JPY 1,180.
Beyond its partnered assets, the firm advances an extensive proprietary pipeline powered by its NxWave GPCR structure-based drug discovery platform. The technology centers on G protein-coupled receptor targets to discover specialty medicines designed to address therapeutic gaps within Japan and international markets.
Keep reading